{"id":"W1987945639","doi":"10.1016/j.ejca.2011.10.035","title":"Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; Ottawa Hospital; Alberta Health Services","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Erlotinib; Internal medicine; Comorbidity; Gemcitabine; Hazard ratio; Erlotinib Hydrochloride; Proportional hazards model; Pancreatic cancer; Placebo; Oncology; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001191567,0.0002225454,0.00114311,0.0001826876,0.00004179494,0.00001073426,0.0001868507,0.0000473967,0.0004912073],"category_scores_gemma":[0.0004711538,0.0001414553,0.00007560426,0.0001794152,0.0002311268,0.0001427118,0.00006900942,0.0004554982,0.000002598141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001946414,"about_ca_system_score_gemma":0.0006969401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00122748,"about_ca_topic_score_gemma":0.0007566581,"domain_scores_codex":[0.9971805,0.000553935,0.001040129,0.0002538369,0.0006468451,0.0003247037],"domain_scores_gemma":[0.9979628,0.0003231712,0.0007927097,0.0002606172,0.0003783524,0.0002823139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8552665,0.001101165,0.1226995,0.00007498229,0.0005468721,0.001686267,0.00370615,0.00001597012,0.0002389266,0.000007314997,0.0004197167,0.01423666],"study_design_scores_gemma":[0.4512703,0.009352754,0.5368446,0.001004031,0.0004517619,0.00001035532,0.0001581123,0.00005243323,0.0000920338,0.00001459003,0.0006021816,0.0001468448],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941168,0.0007016988,0.00004628544,0.000150942,0.0003216321,0.0008638304,0.0001322398,0.000008013461,0.003658494],"genre_scores_gemma":[0.9960442,0.00161593,0.0009578575,0.00009492284,0.0003435047,0.00001384734,0.00001627599,0.00004262785,0.0008708796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4141451,"threshold_uncertainty_score":0.576838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0716409338928136,"score_gpt":0.3556097789209846,"score_spread":0.283968845028171,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}